<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The expression of a truncated 61K mu chain in the Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> lien P3HR-1 and a derived <z:chebi fb="0" ids="7805">ouabain</z:chebi> and TG-resistant subline, PUT, and in various somatic cell hybrids with PUT as one of their parents is described </plain></SENT>
<SENT sid="1" pm="."><plain>Both PUT and P3HR-1 contain intracellular mu and kappa chains, but express no membrane immunoglobulin </plain></SENT>
<SENT sid="2" pm="."><plain>Immunoprecipitation of <z:chebi fb="32" ids="36927">14C</z:chebi>-labeled amino acid or [3H]<z:chebi fb="0" ids="5417">glucosamine</z:chebi>-labeled P3HR-1 extracts with anti-mu serum brought down the same 61K mu chain </plain></SENT>
<SENT sid="3" pm="."><plain>Anti-light-chain sera did not precipitate the truncated mu chain </plain></SENT>
<SENT sid="4" pm="."><plain>P3HR-1 is a clonal derivative of the Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) line Jijoye </plain></SENT>
<SENT sid="5" pm="."><plain>The parental Jijoye line is membrane-IgM positive and contains two <z:mpath ids='MPATH_458'>normal</z:mpath>-sized mu chains </plain></SENT>
<SENT sid="6" pm="."><plain>Both are precipitable by anti-mu and anti-kappa sera </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, anti-mu also precipitated a 61K mu chain </plain></SENT>
<SENT sid="8" pm="."><plain>A 61K mu chain was also identified in the following somatic hybrids: PICATPO, an autohybrid of two different P3HR-1 sublines, PUTRAL and PUT/ARH-77, derived from the fusion of PUT with the membrane-IgG-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> line Rael and the lymphoblastoid cell line (LCL) ARH-77, respectively, and the HP-1 (PUT/<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60) hybrid, derived from the fusion of PUT with the granulocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> line, <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60 </plain></SENT>
<SENT sid="9" pm="."><plain>The 61K mu chain could not be detected in some other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> hybrid combinations, namely RAMPUT (PUT/Ramos) and NAMPUT (PUT/Namalva) </plain></SENT>
<SENT sid="10" pm="."><plain>The anti-light-chain serum (lambda or kappa) had no detectable effect on the truncated 61K mu chain in any of the cases tested, suggesting a lack of assembly between the 61K mu chain and the light chain </plain></SENT>
</text></document>